|89.74||+0.17 / +0.19%|
Data as of 3:59pm ET
|89.74||0.00 / 0.00%|
The 7 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 108.00, with a high estimate of 134.00 and a low estimate of 73.00. The median estimate represents a +20.35% increase from the last price of 89.74.
The current consensus among 9 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.